TELA Bio, Inc.

Good afternoon, ladies and gentlemen, and welcome to the TeleBio second quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. Following the prepared remarks, there'll be a question and answer session. Please be advised that today's conference is being recorded. I will now like to turn the conference over to Louisa Smith.

Thank you, Lisa, and good afternoon, everyone. Earlier today, Tela Bio released financial results for the second quarter and to June 30th, 2026. A copy of the press release is available on the company's website. Joining me on today's call are Joe Capper, Chairman of the Board, Heather Goetz, Chief Executive Officer, Jeff Blizzard, President, Roberto Cuca, Chief Operating Officer and Chief Financial Officer, and Jim Hagen, Senior Vice President of Strategic Operations and Marketing. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's quarterly reports on Forms 10Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, regarding product development, pipeline opportunities, sales and marketing strategies, and the impact of various additional risk factors as identified in our regulatory filings. With that, I'll now turn the call over to Joe.

Thank you, Louisa. Good afternoon, and thank you for joining Telebio's second quarter 2026 earnings call. I will start the call with a few comments about the important leadership change announced last week naming Heather Goetz as the new Chief Executive Officer and Director of Telebio, then turned the call over to the management team for an update on the business. Heather brings a proven track record of driving operational excellence, leading organizations through complex business and financial transformations, and creating long-term value. We are confident that under Heather's leadership, Telebio will build on its strong foundation expand its impact for patients and surgeons and deliver value for our shareholders and employees. On behalf of the board, I also want to extend our sincere gratitude to Tony Koblish for his vision, leadership, and entrepreneurial spirit in founding Telebio and guiding the company through its early growth stage. Tony's commitment to innovation led to the development of Obitex and helped establish Telebio as a leader in soft tissue reconstruction. We are deeply appreciative of his many contributions and wish him continued success in his future endeavors. I will now turn the call over to Heather.